Drug company accused of breaking advertising regulationsBMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7399.1106-b (Published 22 May 2003) Cite this as: BMJ 2003;326:1106
- Fabian Waechter
The Drug and Therapeutics Bulletin has accused the drug company Novartis of breaching advertising regulations in its advertisement for pimecrolimus, a new cream for treating dermatitis (2003;41(5):33-6).
A recent review by the bulletin resulted in three criticisms. The main concern was that while the licence limits the use to patients aged 2 years and older, the recent advertisement, published in many medical journals, shows a baby who looks younger than 2 years, implying that the cream could be used on babies below that age. The bulletin is consequently demanding that the drug's licence be withdrawn.
But a spokesman …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial